Other
Hepatic Steatosis
15
Pipeline Programs↗
2
Active Trials↗
13
Companies Involved↗
Hepatic steatosis is an emerging landscape with 15 programs across 13 companies. The most active players are CD Pharma India Pvt. Ltd., EMD Serono, Mirum Pharmaceuticals, Inc.. 7 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 11
Phase 32
Analysis
Trial Status
10
clinical trials
Completed5 · 50%
Unknown status2 · 20%
Recruiting1 · 10%
Terminated1 · 10%
Not yet recruiting1 · 10%
Clinical Trials
Trial Activity
10 trials
Effect of a GnRH Analog on Hepatic Steatosis
Recruiting·—·Phase 4·NCT06523530·62 enrolled
Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes
Not yet recruiting·—·Phase 3·NCT06691412·100 enrolled
Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients
Completed·—·Phase 4·NCT05474560·90 enrolled
Hepatic Steatosis and Pituitary Gland Failure, Evaluation by Nuclear Magnetic Resonance (NMR) Imaging
Completed·—·N/A·NCT02814240·21 enrolled
The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover
Completed·—·N/A·NCT04859322·20 enrolled
Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis
Unknown status·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·Phase 4·NCT02051842·100 enrolled
A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis
Unknown status·—·Phase 2·NCT02574325·11 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)